Literature DB >> 26322846

Human Leukocyte Antigen-G (HLA-G) Expression in Cancers: Roles in Immune Evasion, Metastasis and Target for Therapy.

Aifen Lin1, Wei-Hua Yan1.   

Abstract

Aberrant induction of human leukocyte antigen-G (HLA-G) expression has been observed in various malignancies and is strongly associated with tumor immune escape, metastasis and poor prognosis. To date, great achievements have been made in understanding the underlying mechanisms of HLA-G involved in tumor progression. HLA-G could lead to tumor evasion by inhibition of immune cell cytolysis, differentiation and proliferation and inhibition of cytokine production, induction of immune cell apoptosis, generation of regulatory cells and expansion of myeloid-derived suppressive cells and by impairment of chemotaxis. Moreover, HLA-G could arm tumor cells with a higher invasive and metastatic potential with the upregulation of tumor-promoting factor expression such as matrix metalloproteinases (MMPs), indicating that ectopic HLA-G expression could render multiple effects during the progression of malignancies. In this review, we summarized the mechanisms of HLA-G involved in promoting tumor cell immune escaping, metastasis and disease progression. Special attention will be paid to its significance as an attractive therapeutic target in cancers.

Entities:  

Year:  2015        PMID: 26322846      PMCID: PMC4749493          DOI: 10.2119/molmed.2015.00083

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  114 in total

1.  HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: impact of the HLA-G 14 base pair (rs66554220) polymorphism.

Authors:  Roberta Rizzo; Valentina Audrito; Paola Vacca; Davide Rossi; Davide Brusa; Marina Stignani; Daria Bortolotti; Giovanni D'Arena; Marta Coscia; Luca Laurenti; Francesco Forconi; Gianluca Gaidano; Maria Cristina Mingari; Lorenzo Moretta; Fabio Malavasi; Silvia Deaglio
Journal:  Haematologica       Date:  2013-12-20       Impact factor: 9.941

2.  Analysis of HLA-G gene polymorphism and protein expression in invasive breast ductal carcinoma.

Authors:  Caroline Steglich Ramos; Andréia Souza Gonçalves; Larissa Cardoso Marinho; Melissa Ameloti Gomes Avelino; Vera Aparecida Saddi; Aryanne Cristina Lopes; Renata Toscano Simões; Isabela Jubé Wastowski
Journal:  Hum Immunol       Date:  2014-04-20       Impact factor: 2.850

Review 3.  The emerging role of soluble HLA-G in the control of chemotaxis.

Authors:  Fabio Morandi; Nathalie Rouas-Freiss; Vito Pistoia
Journal:  Cytokine Growth Factor Rev       Date:  2014-05-13       Impact factor: 7.638

4.  High Expression of Human Leukocyte Antigen-G is Associated with a Poor Prognosis in Patients with PDAC.

Authors:  Y-F Xu; Y Lu; H Cheng; J Jiang; J Xu; J Long; L Liu; Q Ni; C Liu; X-J Yu
Journal:  Curr Mol Med       Date:  2015       Impact factor: 2.222

5.  Multiple steps of HLA-G in ovarian carcinoma metastasis: alter NK cytotoxicity and induce matrix metalloproteinase-15 (MMP-15) expression.

Authors:  Aifen Lin; Hui-Hui Xu; Dan-Ping Xu; Xia Zhang; Qing Wang; Wei-Hua Yan
Journal:  Hum Immunol       Date:  2012-12-08       Impact factor: 2.850

6.  MT1-MMP expression in first-trimester placental tissue is upregulated in type 1 diabetes as a result of elevated insulin and tumor necrosis factor-alpha levels.

Authors:  Ursula Hiden; Elisabeth Glitzner; Marina Ivanisevic; Josip Djelmis; Christian Wadsack; Uwe Lang; Gernot Desoye
Journal:  Diabetes       Date:  2007-10-10       Impact factor: 9.461

7.  Association between the HLA-G molecule and lymph node metastasis in papillary thyroid cancer.

Authors:  Larissa Mesquita Nunes; Flávio Monteiro Ayres; Isadora Carvalho Medeiros Francescantonio; Vera Aparecida Saddi; Melissa Ameloti Gomes Avelino; Rita de Cássia Gonçalves Alencar; Rosana Correa da Silva; Alexandre J Meneghini; Isabela Jubé Wastowski
Journal:  Hum Immunol       Date:  2012-12-20       Impact factor: 2.850

Review 8.  Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the ugly.

Authors:  Paolo Serafini
Journal:  Immunol Res       Date:  2013-12       Impact factor: 4.505

9.  Significance of tumour cell HLA-G5/-G6 isoform expression in discrimination for adenocarcinoma from squamous cell carcinoma in lung cancer patients.

Authors:  Wei-Hua Yan; Di Liu; Hai-Yan Lu; Ying-Ying Li; Xia Zhang; Aifen Lin
Journal:  J Cell Mol Med       Date:  2015-02-16       Impact factor: 5.310

10.  Human tolerogenic DC-10: perspectives for clinical applications.

Authors:  Giada Amodio; Silvia Gregori
Journal:  Transplant Res       Date:  2012-09-28
View more
  43 in total

1.  Stochastic modeling of tumor progression and immune evasion.

Authors:  Jason T George; Herbert Levine
Journal:  J Theor Biol       Date:  2018-09-12       Impact factor: 2.691

2.  Impacts of the MHC class I-like XNC10 and innate-like T cells on tumor tolerance and rejection in the amphibian Xenopus.

Authors:  Maureen Banach; Eva-Stina Edholm; Xavier Gonzalez; Abdellatif Benraiss; Jacques Robert
Journal:  Carcinogenesis       Date:  2019-07-20       Impact factor: 4.944

3.  Tumor immunology viewed from alternative animal models-the Xenopus story.

Authors:  Maureen Banach; Jacques Robert
Journal:  Curr Pathobiol Rep       Date:  2017-01-26

Review 4.  Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape.

Authors:  Malte Mohme; Sabine Riethdorf; Klaus Pantel
Journal:  Nat Rev Clin Oncol       Date:  2016-09-20       Impact factor: 66.675

5.  LILRB1 Blockade Enhances Bispecific T Cell Engager Antibody-Induced Tumor Cell Killing by Effector CD8+ T Cells.

Authors:  Aeryon Kim; Chia-Jung Han; Ian Driver; Aleksandra Olow; Andrew K Sewell; Zemin Zhang; Wenjun Ouyang; Jackson G Egen; Xin Yu
Journal:  J Immunol       Date:  2019-06-28       Impact factor: 5.422

Review 6.  Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets.

Authors:  Aswathy R Devan; Bhagyalakshmi Nair; Ayana R Kumar; Balachandran S Vinod; Lekshmi R Nath
Journal:  Mol Biol Rep       Date:  2021-10-20       Impact factor: 2.316

7.  The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line Panel.

Authors:  Anne Monks; Yingdong Zhao; Curtis Hose; Hossein Hamed; Julia Krushkal; Jianwen Fang; Dmitriy Sonkin; Alida Palmisano; Eric C Polley; Laura K Fogli; Mariam M Konaté; Sarah B Miller; Melanie A Simpson; Andrea Regier Voth; Ming-Chung Li; Erik Harris; Xiaolin Wu; John W Connelly; Annamaria Rapisarda; Beverly A Teicher; Richard Simon; James H Doroshow
Journal:  Cancer Res       Date:  2018-10-24       Impact factor: 12.701

Review 8.  Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.

Authors:  Zachary B Davis; Daniel A Vallera; Jeffrey S Miller; Martin Felices
Journal:  Semin Immunol       Date:  2017-09-05       Impact factor: 11.130

Review 9.  The Immune Microenvironment and Cancer Metastasis.

Authors:  Asmaa El-Kenawi; Kay Hänggi; Brian Ruffell
Journal:  Cold Spring Harb Perspect Med       Date:  2020-04-01       Impact factor: 6.915

10.  Specific and Aspecific Molecular Checkpoints as Potential Targets for Dismantling Tumor Hierarchy and Preventing Relapse and Metastasis Through Shielded Cytolytic Treatments.

Authors:  Giovanni Manzo
Journal:  Front Cell Dev Biol       Date:  2021-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.